Trifecta Capital Advisors’s iShares Biotechnology ETF IBB Stock Holding History

Trifecta Capital Advisors’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$57.1K	Hold	300	–	–	0.01%	185
2026 Q1	$50.7K	Buy	300 +25	+9%	+$4.28K	0.01%	178
2025 Q4	$46.4K	Hold	275	–	–	0.01%	169
2025 Q3	$39.7K	Hold	275	–	–	0.01%	179
2025 Q2	$34.8K	Hold	275	–	–	0.01%	188
2025 Q1	$35.2K	Hold	275	–	–	0.01%	161
2024 Q4	$36.4K	Hold	275	–	–	0.01%	158
2024 Q3	$40K	Hold	275	–	–	0.01%	155
2024 Q2	$37.7K	Hold	275	–	–	0.01%	158
2024 Q1	$37.7K	Hold	275	–	–	0.01%	150
2023 Q4	$37.4K	Hold	275	–	–	0.01%	147
2023 Q3	$33.6K	Hold	275	–	–	0.01%	155
2023 Q2	$34.9K	Hold	275	–	–	0.01%	159
2023 Q1	$35.5K	Hold	275	–	–	0.01%	158
2022 Q4	$36.1K	Buy	+275	New	+$35.5K	0.01%	141

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Commerce Bank Kansas City, Missouri $22.8B AUM 28.56% 1-Year Est. Return

Trifecta Capital Advisors's IBB Position: Q2 2026 in Review

Trifecta Capital Advisors held its iShares Biotechnology ETF (IBB) position steady in Q2 2026 at 300 shares worth $57.1K. The position accounts for 0.01% of the portfolio, ranked #185.

Trifecta Capital Advisors first reported a position in IBB in Q4 2022 and has held it in 15 quarters since. 957 funds tracked by Wall St. Rank hold IBB as of Q2 2026.

Trifecta Capital Advisors held 300 shares of iShares Biotechnology ETF worth $57.1K as of Q2 2026.
Trifecta Capital Advisors left its iShares Biotechnology ETF share count unchanged in Q2 2026.
iShares Biotechnology ETF made up 0.01% of Trifecta Capital Advisors's portfolio in Q2 2026, its #185 holding.
Trifecta Capital Advisors first reported a position in iShares Biotechnology ETF in Q4 2022 and has held it in 15 quarters since.
957 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q2 2026.

Based on Trifecta Capital Advisors's 13F filing for Q2 2026, filed 3 Aug 2026.